TY  - GEN
AU  - Papi,Alberto
AU  - Jones,Paul W
AU  - Dalvi,Prashant S
AU  - McAulay,Kirsten
AU  - McIver,Tammy
AU  - Dissanayake,Sanjeeva
TI  - The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
SN  - 1178-2005
PY  - 2016///0920
KW  - Administration, Inhalation
KW  - Adrenal Cortex Hormones
KW  - administration & dosage
KW  - Adrenergic beta-2 Receptor Agonists
KW  - Androstadienes
KW  - Biomarkers
KW  - blood
KW  - Bronchodilator Agents
KW  - Chemokines, CC
KW  - Clinical Protocols
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Drug Combinations
KW  - Ethanolamines
KW  - Fluticasone
KW  - Forced Expiratory Volume
KW  - Formoterol Fumarate
KW  - Humans
KW  - Lung
KW  - drug effects
KW  - Pulmonary Disease, Chronic Obstructive
KW  - Pulmonary Surfactant-Associated Protein D
KW  - Recovery of Function
KW  - Research Design
KW  - Spirometry
KW  - Surveys and Questionnaires
KW  - Time Factors
KW  - Treatment Outcome
KW  - Vital Capacity
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.2147/COPD.S93375
ER  -